Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Common Equity (2021 - 2026)

TriSalus Life Sciences has reported Common Equity over the past 6 years, most recently at $12.8 million for Q1 2026.

  • For Q1 2026, Common Equity rose 137.26% year-over-year to $12.8 million; the TTM value through Mar 2026 reached $12.8 million, up 137.26%, while the annual FY2025 figure was -$33.9 million, 30.77% down from the prior year.
  • Common Equity for Q1 2026 was $12.8 million at TriSalus Life Sciences, up from -$33.9 million in the prior quarter.
  • Over five years, Common Equity peaked at $12.8 million in Q1 2026 and troughed at -$198.4 million in Q2 2023.
  • A 5-year average of -$72.1 million and a median of -$33.9 million in 2025 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 346.43% in 2024 and later surged 137.26% in 2026.
  • Year by year, Common Equity stood at -$177.1 million in 2022, then surged by 84.72% to -$27.1 million in 2023, then grew by 4.33% to -$25.9 million in 2024, then plummeted by 30.77% to -$33.9 million in 2025, then soared by 137.82% to $12.8 million in 2026.
  • Business Quant data shows Common Equity for TLSI at $12.8 million in Q1 2026, -$33.9 million in Q4 2025, and -$26.7 million in Q3 2025.